Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

GLP-1 agonists remain out of reach for many due to high costs, leading some patients to turn to unsafe compounded versions ...

The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...

Four of the 10 medications Statista anticipates will yield the largest sales in 2026 are GLP-1 medications ... drug Mounjaro joined the top 10 list and secured the third spot with projected ...

Drug compounding is allowed when drugs are on the FDA's shortage list, or in circumstances when ... FDA's decision to halt compounded versions of GLP-1 drugs. The FDA says state-licensed ...